Technology platform

Despite major R&D efforts, prosthetic devices in cardiovascular medicine are still associated with a number of problems (inflammation, thrombosis, …) stemming from the fact that these are foreign materials, not accepted by the body. This in turn triggers a series of unwanted biological reactions which ultimately result in device failure, repeat surgery and significant healthcare costs.

Anethon’s founders have developed a second generation biomimetic coating. Comprised of protein components, the coating when applied to cardiovascular prostheses, provides a surface that helps the body to accept these implanted devices as its own tissue, thus avoiding and/or delaying the failure of the implanted prostheses.




To date Anethon has successfully applied its coating to both synthetic blood vessels (carotid artery) and heart valves (bovine pericardium and homografts) in a juvenile sheep model:

• Coating of synthetic vascular grafts doubles endothelialisation, decreases thrombosis and reduces neointimal hyperplasia resulting in an increase of the luminal surface by 40%.
• Coating of heart tissue valves prevents calcification and pannus formation. Results suggest that the use of (decellularized) aortic homografts coated with FN/SDF-1a becomes justified, increasing the availability of homografts for Right Ventricular Outflow Tract reconstruction by 50%.

Anethon has granted patents in Europe, China and Japan and patent applications in all major other countries.